Faslodex Advanced Breast Cancer Local Chinese Study
Study identifier:D6997L00004
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A double blind, double dummy, randomised, multicentre study to compare the efficacy and safety of Fulvestrant 250mg with Arimidex 1mg as a secondary-line therapy in the postmenopausal women with oestrogen receptor positive advanced breast cancer
Medical condition
Advanced breast cancer
Phase
Phase 3
Healthy volunteers
No
Study drug
Fulvestrant, Anastrozole
Sex
Female
Actual Enrollment
234
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Nov 2005
Primary Completion Date: -
Study Completion Date: 01 Sept 2007
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: 1 Anastrozole | Drug: Anastrozole 1 mg tablet Other Name: Arimidex Other Name: ZD1033 |
| Experimental: 2 Anastrozole + Fulvestrant | Drug: Fulvestrant 250 mg intramuscular injection Other Name: Faslodex Other Name: ZD9238 Drug: Anastrozole 1 mg tablet Other Name: Arimidex Other Name: ZD1033 |
Contacts
Investigators
Principal Investigator
Breast Cancer Established Brands Team Medical Science Director
AstraZeneca
